Advanced Biomed (ADVB) Stock Analysis & AI Equity Report

Medical - Diagnostics & Research USD Explore free reports

Advanced Biomed (ADVB) overview

Advanced Biomed (ADVB) stock analysis and AI equity research. For financial year 2026, Valuatum's model shows revenue of USD 0.1m and operating profit of USD -6.2m; the year-end share price was 4.65 USD and market capitalisation was USD 7.7m. Advanced Biomed is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Advanced Biomed's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 12.3mFY 2026
Share price4.65 USDFY 2026 year end
RevenueUSD 0.1mFY 2026
Operating profitUSD -6.2mFY 2026
Net earningsUSD 6.7mFY 2026
Market capitalisationUSD 7.7mFY 2026 year end

About Advanced Biomed

Advanced Biomed is a holding company that shifted from biomedical operations to enterprise AI financial verification after disposing of its biomedical businesses. It develops and operates FinTruth, a platform that checks financial analysis and AI-generated financial content against source documents and financial rules, producing traceable, auditable results. Its target customers include financial institutions, professional services firms, and financial technology companies.

Generate the Advanced Biomed report

Advanced Biomed is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Advanced Biomed and represent financial year 2026. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Advanced Biomed

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.